🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
BAROPHARM Co., Ltd. (KOSDAQ:0153R0)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,700.00
-610.00 (-8.34%)
At close: Nov 17, 2026

BAROPHARM Statistics

Total Valuation

BAROPHARM has a market cap or net worth of KRW 80.17 billion. The enterprise value is 71.03 billion.

Market Cap80.17B
Enterprise Value 71.03B

Important Dates

The next estimated earnings date is Friday, April 9, 2027.

Earnings Date Apr 9, 2027
Ex-Dividend Date n/a

Share Statistics

BAROPHARM has 11.97 million shares outstanding. The number of shares has increased by 50.93% in one year.

Current Share Class 11.97M
Shares Outstanding 11.97M
Shares Change (YoY) +50.93%
Shares Change (QoQ) +2.80%
Owned by Insiders (%) 40.36%
Owned by Institutions (%) 4.48%
Float 5.00M

Valuation Ratios

The trailing PE ratio is 42.02.

PE Ratio 42.02
Forward PE n/a
PS Ratio 0.55
PB Ratio 2.12
P/TBV Ratio 2.32
P/FCF Ratio n/a
P/OCF Ratio 57.47
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 47.24
EV / Sales 0.49
EV / EBITDA 16.99
EV / EBIT 21.76
EV / FCF n/a

Financial Position

The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.41.

Current Ratio 1.25
Quick Ratio 0.79
Debt / Equity 0.41
Debt / EBITDA 3.72
Debt / FCF n/a
Interest Coverage 6.75

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) 10.79%
Return on Capital Employed (ROCE) 8.32%
Weighted Average Cost of Capital (WACC) n/a
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, BAROPHARM has paid 98.86 million in taxes.

Income Tax 98.86M
Effective Tax Rate 6.17%

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average n/a
200-Day Moving Average n/a
Relative Strength Index (RSI) n/a
Average Volume (20 Days) 3,189,502

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, BAROPHARM had revenue of KRW 145.03 billion and earned 1.50 billion in profits. Earnings per share was 159.45.

Revenue145.03B
Gross Profit 25.38B
Operating Income 3.26B
Pretax Income 1.60B
Net Income 1.50B
EBITDA 4.18B
EBIT 3.26B
Earnings Per Share (EPS) 159.45
Full Income Statement

Balance Sheet

The company has 24.70 billion in cash and 15.56 billion in debt, with a net cash position of 9.14 billion or 764.22 per share.

Cash & Cash Equivalents 24.70B
Total Debt 15.56B
Net Cash 9.14B
Net Cash Per Share 764.22
Equity (Book Value) 37.74B
Book Value Per Share 3,723.48
Working Capital 13.42B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.39 billion and capital expenditures -20.59 billion, giving a free cash flow of -19.19 billion.

Operating Cash Flow 1.39B
Capital Expenditures -20.59B
Depreciation & Amortization 915.89M
Net Borrowing 13.65B
Free Cash Flow -19.19B
FCF Per Share -1,603.97
Full Cash Flow Statement

Margins

Gross margin is 17.50%, with operating and profit margins of 2.25% and 1.04%.

Gross Margin 17.50%
Operating Margin 2.25%
Pretax Margin 1.10%
Profit Margin 1.04%
EBITDA Margin 2.88%
EBIT Margin 2.25%
FCF Margin n/a

Dividends & Yields

BAROPHARM does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -50.93%
Shareholder Yield -50.93%
Earnings Yield 2.38%
FCF Yield -23.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

BAROPHARM has an Altman Z-Score of 1.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.27
Piotroski F-Score 3